Literature DB >> 25544397

Endothelin receptors, renal effects and blood pressure.

Erika I Boesen1.   

Abstract

The endothelin system has emerged as a key player in the renal control of salt and water homeostasis, exerting profound effects on both the renal vasculature and tubular epithelial cells. Recent advances include new actions of endothelins in the glomerulus, an emerging role for the ETA receptor in chronic kidney disease (CKD) progression and in tubular function, and a more detailed understanding of the tubular response to high salt intake. A large body of evidence also implicates dysfunction of the endothelin system in hypertension, particularly salt-sensitive hypertension, although recent data suggests important sex-differences may exist. Finally, clinical trials indicate that antagonists of endothelin receptors hold great promise in treating resistant hypertension and proteinuric renal disease.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25544397     DOI: 10.1016/j.coph.2014.12.007

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  19 in total

1.  Target-Mediated Drug Disposition Pharmacokinetic-Pharmacodynamic Model of Bosentan and Endothelin-1.

Authors:  Anke-Katrin Volz; Andreas Krause; Walter Emil Haefeli; Jasper Dingemanse; Thorsten Lehr
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

Review 2.  Endothelium-derived ET-1 and the development of renal injury.

Authors:  Carmen De Miguel; David M Pollock; Jennifer S Pollock
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-05-20       Impact factor: 3.619

Review 3.  Endothelin-1 and the kidney: new perspectives and recent findings.

Authors:  Carmen De Miguel; Joshua S Speed; Malgorzata Kasztan; Eman Y Gohar; David M Pollock
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-01       Impact factor: 2.894

Review 4.  Endothelin Receptor Antagonists: New Hope for Renal Protection?

Authors:  Sheldon Tobe; Donald E Kohan; Ranjit Singarayer
Journal:  Curr Hypertens Rep       Date:  2015-07       Impact factor: 5.369

Review 5.  Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy.

Authors:  Stacy A Johnson; Robert F Spurney
Journal:  Am J Physiol Renal Physiol       Date:  2015-09-02

Review 6.  Endothelin, sex, and pregnancy: unique considerations for blood pressure control in females.

Authors:  Ellen E Gillis; Jennifer M Sasser; Jennifer C Sullivan
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-03-02       Impact factor: 3.619

Review 7.  Kidney tubules: intertubular, vascular, and glomerular cross-talk.

Authors:  David A Ferenbach; Joseph V Bonventre
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-05       Impact factor: 2.894

Review 8.  Update on Endothelin Receptor Antagonists in Hypertension.

Authors:  Michel Burnier
Journal:  Curr Hypertens Rep       Date:  2018-05-19       Impact factor: 5.369

Review 9.  Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling.

Authors:  Caroline R Sussman; Xiaofang Wang; Fouad T Chebib; Vicente E Torres
Journal:  Cell Signal       Date:  2020-04-23       Impact factor: 4.315

10.  Target-Mediated Population Pharmacokinetic Modeling of Endothelin Receptor Antagonists.

Authors:  Anke-Katrin Volz; Jasper Dingemanse; Andreas Krause; Thorsten Lehr
Journal:  Pharm Res       Date:  2019-12-10       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.